Research Tissue Bank

Description

This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: - Peripheral blood - Bone marrow - Bone marrow biopsy - A phlebotomized unit of blood - Spleen cells - Toenail clippings This material will be used for the study of Myeloproliferative Disorders (MPD) by researchers. The goals of this research study are to understand the causes of MPDs, how to diagnose them more easily and how to treat them better. MPD is a disease affecting hematopoietic stem cells. Hematopoietic stem cells are cells that make blood cells. These stem cells grow in the center portion of the bones called bone marrow. Under some conditions, these cells are also found in blood. There are several diseases, which are classified as MPD. These include polycythemia vera (too many red blood cells), essential thrombocythemia (too many platelets), and idiopathic myelofibrosis (abnormal blood cells and fibers build up in the bone marrow). These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments.

Study Start Date

September 2007

Estimated Completion Date

June 2019

Interventions

No interventions cited

Specialties

  • Internal Medicine: Hematology/Oncology
  • Oncology: Myeloproliferative Dz
  • Physician Assistant: Hematology/Oncology

MeSH Terms

  • Polycythemia
  • Polycythemia Vera
  • Primary Myelofibrosis
  • Thrombocythemia
  • Thrombocytosis

Study ID

Myeloproliferative Disorders-Research Consortium -- MPD-RC 106

Status

Unknown

Trial ID

NCT00666549

Study Type

Observational

Trial Phase

N/A

Enrollment Quota

400

Sponsor

Myeloproliferative Disorders-Research Consortium

Inclusion Criteria

  • Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) are eligible.
  • Newly diagnose MPD patients as well as previously treated for a MPD are eligible.
  • Signed informed consent is required from each patient at the time of enrollment.

Exclusion Criteria

  • Patients currently participating in experimental treatment arms of MPD-RC protocols, or other experimental treatment protocols are not eligible during the period they are on study.

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (12)

Study Location Distance Name Phone Email
Mount Sinai Medical Center - New York, New York 46.8 miles None None None
Weill Cornell University - Washington, District of Columbia 50.7 miles None None None
University of Pennsylvania - Philadelphia, Pennsylvania 133.3 miles None None None
Johns Hopkins - Baltimore, Maryland 220.0 miles None None None
Johns Hopkins - Baltimore, Maryland 220.0 miles None None None
University of Georgetown - Washington, District of Columbia 258.2 miles None None None
Roswell Park - Buffalo, New York 310.8 miles None None None
Roswell Park - Buffalo, New York 310.8 miles None None None
University of Illinois at Chicago - Chicago, Illinois 748.9 miles None None None
University of Illinois at Chicago - Chicago, Illinois 748.9 miles None None None
University of Utah - Salt Lake City, Utah 2,002.5 miles None None None
Palo Alto Medical Foundation Research Institute - Palo Alto, California 2,598.6 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.